JP2011518566A - Ａｂｉ１／ｈｓｓｈ３ｂｐ１コンディショナルノックアウトマウス - Google Patents
Ａｂｉ１／ｈｓｓｈ３ｂｐ１コンディショナルノックアウトマウス Download PDFInfo
- Publication number
- JP2011518566A JP2011518566A JP2011506500A JP2011506500A JP2011518566A JP 2011518566 A JP2011518566 A JP 2011518566A JP 2011506500 A JP2011506500 A JP 2011506500A JP 2011506500 A JP2011506500 A JP 2011506500A JP 2011518566 A JP2011518566 A JP 2011518566A
- Authority
- JP
- Japan
- Prior art keywords
- hssh3bp1
- abi1
- gene
- mouse
- loxp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100028247 Abl interactor 1 Human genes 0.000 title claims abstract description 255
- 238000011813 knockout mouse model Methods 0.000 title claims abstract description 26
- 101000724225 Homo sapiens Abl interactor 1 Proteins 0.000 title description 2
- 101150005804 ABI1 gene Proteins 0.000 claims abstract description 250
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 221
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 210000004602 germ cell Anatomy 0.000 claims abstract description 10
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 3
- 230000000392 somatic effect Effects 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 163
- 229930193140 Neomycin Natural products 0.000 claims description 71
- 229960004927 neomycin Drugs 0.000 claims description 71
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 66
- 108700028369 Alleles Proteins 0.000 claims description 57
- 241000699670 Mus sp. Species 0.000 claims description 53
- 108010051219 Cre recombinase Proteins 0.000 claims description 41
- 210000002307 prostate Anatomy 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 26
- 101001010097 Shigella phage SfV Bactoprenol-linked glucose translocase Proteins 0.000 claims description 25
- 239000003550 marker Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 21
- 230000005012 migration Effects 0.000 claims description 19
- 238000013508 migration Methods 0.000 claims description 19
- 238000009395 breeding Methods 0.000 claims description 14
- 230000001488 breeding effect Effects 0.000 claims description 14
- 210000001161 mammalian embryo Anatomy 0.000 claims description 14
- 230000009087 cell motility Effects 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 230000002688 persistence Effects 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 description 66
- 108091028043 Nucleic acid sequence Proteins 0.000 description 55
- 230000014509 gene expression Effects 0.000 description 46
- 238000012217 deletion Methods 0.000 description 42
- 230000037430 deletion Effects 0.000 description 42
- 230000006798 recombination Effects 0.000 description 38
- 238000005215 recombination Methods 0.000 description 38
- 230000002441 reversible effect Effects 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 26
- 208000023958 prostate neoplasm Diseases 0.000 description 25
- 108091033380 Coding strand Proteins 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 22
- 230000035772 mutation Effects 0.000 description 21
- 238000003752 polymerase chain reaction Methods 0.000 description 21
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 16
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 16
- 206010060862 Prostate cancer Diseases 0.000 description 15
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 15
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 15
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 15
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 14
- 101100322030 Drosophila melanogaster Abl gene Proteins 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000003205 genotyping method Methods 0.000 description 11
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 10
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 231100000504 carcinogenesis Toxicity 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000002093 peripheral effect Effects 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 230000036952 cancer formation Effects 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 208000005623 Carcinogenesis Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 229950010131 puromycin Drugs 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108050004693 Abl interactor 1 Proteins 0.000 description 5
- 238000010222 PCR analysis Methods 0.000 description 5
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 5
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 5
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 5
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 5
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
- 102000000395 SH3 domains Human genes 0.000 description 4
- 108050008861 SH3 domains Proteins 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000004292 cytoskeleton Anatomy 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000004287 null lymphocyte Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 108010042121 probasin Proteins 0.000 description 4
- 210000005267 prostate cell Anatomy 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 101710172419 5-azacytidine-induced protein 2 Proteins 0.000 description 3
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 206010068051 Chimerism Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 102100038417 Cytoplasmic FMR1-interacting protein 1 Human genes 0.000 description 3
- 101710181791 Cytoplasmic FMR1-interacting protein 1 Proteins 0.000 description 3
- 241001045988 Neogene Species 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 101150091879 neo gene Proteins 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 108050003506 ABL interactor 2 Proteins 0.000 description 2
- 108010038861 ARG tyrosine kinase Proteins 0.000 description 2
- 102100028221 Abl interactor 2 Human genes 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000006822 Agouti Signaling Protein Human genes 0.000 description 2
- 108010072151 Agouti Signaling Protein Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000484025 Cuniculus Species 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100348669 Mus musculus Nkx3-1 gene Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 108010009711 Phalloidine Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 101150058540 RAC1 gene Proteins 0.000 description 2
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- 102000005890 Spectrin Human genes 0.000 description 2
- 108010019965 Spectrin Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010062653 Wiskott-Aldrich Syndrome Protein Family Proteins 0.000 description 2
- 102100037103 Wiskott-Aldrich syndrome protein family member 2 Human genes 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 108010056929 lyticase Proteins 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 101100005916 Arabidopsis thaliana CER3 gene Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 101150088221 FLP1 gene Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101001139126 Homo sapiens Krueppel-like factor 6 Proteins 0.000 description 1
- 101000963987 Homo sapiens SH3 domain-binding protein 5 Proteins 0.000 description 1
- 102100020679 Krueppel-like factor 6 Human genes 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101000724227 Mus musculus Abl interactor 1 Proteins 0.000 description 1
- 101100299619 Mus musculus Ptpn18 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 102100040119 SH3 domain-binding protein 5 Human genes 0.000 description 1
- 101100220842 Schizosaccharomyces pombe (strain 972 / ATCC 24843) clp1 gene Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 1
- -1 Wave complex Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000002783 cell motility assay Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012240 conditional targeting Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 102000055854 human ABI1 Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005741 malignant process Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- TXBNDGDMWKVRQW-UHFFFAOYSA-M sodium;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]acetate;dodecyl sulfate Chemical compound [Na+].OCC(CO)(CO)NCC(O)=O.CCCCCCCCCCCCOS([O-])(=O)=O TXBNDGDMWKVRQW-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4813008P | 2008-04-25 | 2008-04-25 | |
| US61/048,130 | 2008-04-25 | ||
| PCT/US2009/041846 WO2009132357A1 (en) | 2008-04-25 | 2009-04-27 | Abi1/hssh3bp1 conditional knockout mouse |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011518566A true JP2011518566A (ja) | 2011-06-30 |
| JP2011518566A5 JP2011518566A5 (enExample) | 2012-04-19 |
Family
ID=40823240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506500A Pending JP2011518566A (ja) | 2008-04-25 | 2009-04-27 | Ａｂｉ１／ｈｓｓｈ３ｂｐ１コンディショナルノックアウトマウス |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8110719B2 (enExample) |
| EP (1) | EP2268821A1 (enExample) |
| JP (1) | JP2011518566A (enExample) |
| AU (1) | AU2009240404A1 (enExample) |
| CA (1) | CA2719267A1 (enExample) |
| IL (1) | IL208904A0 (enExample) |
| WO (1) | WO2009132357A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5867671B2 (ja) * | 2011-03-28 | 2016-02-24 | 国立大学法人神戸大学 | コンディショナルノックアウト動物 |
| EP2918166A1 (en) | 2014-03-10 | 2015-09-16 | Westfälische Wilhelms-Universität Münster | TTP/MRP14 double knock out mouse model of psoriasis |
| CA3155265A1 (en) * | 2019-11-04 | 2021-05-14 | Regeneron Pharmaceuticals, Inc. | A rodent model of increased bone mineral density |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038179A1 (en) * | 2000-11-10 | 2002-05-16 | Kissei Pharmaceutical Co., Ltd. | Preventives or remedies for endoplasmic reticulum stress-associated diseases |
| JP2003512053A (ja) * | 1999-10-16 | 2003-04-02 | アルテミス・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 遺伝子破壊用条件付遺伝子トラッピング構築物 |
| JP2003518947A (ja) * | 2000-01-07 | 2003-06-17 | アルテミス・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 誘導可能遺伝子標的化のためのレコンビナーゼのトランスダクション |
| JP2003319734A (ja) * | 2002-05-02 | 2003-11-11 | Japan Science & Technology Corp | Ｍｄ−２遺伝子改変モデル非ヒト動物 |
| WO2004014131A1 (ja) * | 2002-08-09 | 2004-02-19 | Life Science Solutions Co., Ltd. | ノックイン非ヒト動物及び組織特異的ＭｎＳＯＤノックアウト非ヒト動物 |
| WO2005084429A1 (ja) * | 2004-03-04 | 2005-09-15 | Cellseed Inc. | 癌細胞移植動物の製造方法 |
| WO2006004066A1 (ja) * | 2004-07-02 | 2006-01-12 | Locomogene, Inc. | S1-5を含有するタンパク質製剤 |
| JP2006067944A (ja) * | 2004-09-03 | 2006-03-16 | Japan Science & Technology Agency | シナプス成熟障害モデル動物 |
| JP2006521113A (ja) * | 2003-03-28 | 2006-09-21 | 古澤 満 | 所望の形質を生物に迅速に付与する方法およびシステム |
| WO2007030820A2 (en) * | 2005-09-09 | 2007-03-15 | The Johns Hopkins University | Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists |
| WO2007148676A1 (ja) * | 2006-06-20 | 2007-12-27 | Toray Industries, Inc. | 白血病の治療又は予防剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205148B2 (en) * | 2003-06-11 | 2007-04-17 | Regeneron Pharmaceuticals, Inc. | Genome mutation by intron insertion into an embryonic stem cell genome |
-
2009
- 2009-04-27 US US12/430,814 patent/US8110719B2/en not_active Expired - Fee Related
- 2009-04-27 EP EP09734240A patent/EP2268821A1/en not_active Ceased
- 2009-04-27 CA CA2719267A patent/CA2719267A1/en not_active Abandoned
- 2009-04-27 AU AU2009240404A patent/AU2009240404A1/en not_active Abandoned
- 2009-04-27 JP JP2011506500A patent/JP2011518566A/ja active Pending
- 2009-04-27 WO PCT/US2009/041846 patent/WO2009132357A1/en not_active Ceased
-
2010
- 2010-10-24 IL IL208904A patent/IL208904A0/en unknown
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003512053A (ja) * | 1999-10-16 | 2003-04-02 | アルテミス・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 遺伝子破壊用条件付遺伝子トラッピング構築物 |
| JP2003518947A (ja) * | 2000-01-07 | 2003-06-17 | アルテミス・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 誘導可能遺伝子標的化のためのレコンビナーゼのトランスダクション |
| WO2002038179A1 (en) * | 2000-11-10 | 2002-05-16 | Kissei Pharmaceutical Co., Ltd. | Preventives or remedies for endoplasmic reticulum stress-associated diseases |
| JP2003319734A (ja) * | 2002-05-02 | 2003-11-11 | Japan Science & Technology Corp | Ｍｄ−２遺伝子改変モデル非ヒト動物 |
| WO2004014131A1 (ja) * | 2002-08-09 | 2004-02-19 | Life Science Solutions Co., Ltd. | ノックイン非ヒト動物及び組織特異的ＭｎＳＯＤノックアウト非ヒト動物 |
| JP2006521113A (ja) * | 2003-03-28 | 2006-09-21 | 古澤 満 | 所望の形質を生物に迅速に付与する方法およびシステム |
| WO2005084429A1 (ja) * | 2004-03-04 | 2005-09-15 | Cellseed Inc. | 癌細胞移植動物の製造方法 |
| WO2006004066A1 (ja) * | 2004-07-02 | 2006-01-12 | Locomogene, Inc. | S1-5を含有するタンパク質製剤 |
| JP2006067944A (ja) * | 2004-09-03 | 2006-03-16 | Japan Science & Technology Agency | シナプス成熟障害モデル動物 |
| WO2007030820A2 (en) * | 2005-09-09 | 2007-03-15 | The Johns Hopkins University | Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists |
| WO2007148676A1 (ja) * | 2006-06-20 | 2007-12-27 | Toray Industries, Inc. | 白血病の治療又は予防剤 |
Non-Patent Citations (8)
| Title |
|---|
| JPN6012021026; Ｎｅｏｐｌａｓｉａ Ｖｏｌ．３， Ｎｏ．２, 2001, ｐ．９９-１０４ * |
| JPN6012021027; Ｂｉｏｃｈｉｍ． Ｂｉｏｐｈｙｓ． Ａｃｔａ Ｖｏｌ．１７８３, 20080215, ｐ．７３７-７４７ * |
| JPN6012021028; Ｃａｎｃｅｒ Ｒｅｓ． Ｖｏｌ．６４, 2004, ｐ．６０１８-６０２５ * |
| JPN6012021029; Ｊ．Ｎｅｕｒｏｓｃｉ．Ｍｅｔｈ． Ｖｏｌ．７１, 1997, ｐ．１９-２７ * |
| JPN6012052669; Ｓｔｏｃｋａｎｄ Ｊ-Ｄ． ｅｔ ａｌ．: Ｍｅｔｈｏｄｓ ｉｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ ３３７ Ｉｏｎ Ｃｈａｎｎｅｌｓ Ｍｅｔｈｏｄｓ ａｎｄ Ｐｒｏｔｏｃｏｌｓ , 2006, ｐ．１８５-２０５, Ｈｕｍａｎａ Ｐｒｅｓｓ Ｉｎｃ． * |
| JPN6012052670; Ｄｕｔｔｏｎ Ｇ．: 'Ｓｉｔｅ-Ｓｐｅｃｉｆｉｃ Ｒｅｃｏｍｂｉｎａｓｅｓ' Ｔｈｅ Ｓｃｉｅｎｔｉｓｔ［ｏｎｌｉｎｅ］ , 200207, ＬａｂＸ Ｍｅｄｉａ Ｇｒｏｕｐ * |
| JPN6012052671; Ｄｅｖｅｌｏｐｍｅｎｔ Ｖｏｌ．１２９， Ｎｏ．６, 2002, ｐ．１３９７-１４１０ * |
| JPN6012052672; 野田 亮: '生体内における細胞外マトリックス・リモデリングの役割と制御機構の解明' 平成１８年度学術創成研究費中間評価結果［ｏｎｌｉｎｅ］ , 200612, 日本学術振興会 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009132357A1 (en) | 2009-10-29 |
| US8110719B2 (en) | 2012-02-07 |
| US20090271883A1 (en) | 2009-10-29 |
| CA2719267A1 (en) | 2009-10-29 |
| AU2009240404A1 (en) | 2009-10-29 |
| IL208904A0 (en) | 2011-01-31 |
| EP2268821A1 (en) | 2011-01-05 |
| AU2009240404A2 (en) | 2010-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tybulewicz et al. | Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene | |
| Giovannini et al. | Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2 | |
| Davy et al. | Ephrin-B1 forward and reverse signaling are required during mouse development | |
| Meier et al. | Short DNA sequences inserted for gene targeting can accidentally interfere with off‐target gene expression | |
| Trapasso et al. | Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis | |
| Kawamata et al. | Mice deficient in Dmrt7 show infertility with spermatogenic arrest at pachytene stage | |
| CN105950654B (zh) | 一种人源化的转基因动物 | |
| Jin et al. | Targeted deletion of Hsf1, 2, and 4 genes in mice | |
| JP5075641B2 (ja) | 遺伝子改変動物およびその用途 | |
| US8110719B2 (en) | ABI1 conditional knockout mouse | |
| US9295239B2 (en) | MO-1 conditional knock-out non-human animal and uses thereof | |
| WO2001056375A1 (en) | Tob gene-defective knockout nonhuman mammal | |
| Omi et al. | Mutation of Dock5, a member of the guanine exchange factor Dock180 superfamily, in the rupture of lens cataract mouse | |
| WO1997035967A2 (en) | Transgenic organisms with altered telomerase activity | |
| Reid et al. | Generation and characterization of a novel neural crest marker allele, Inka1‐LacZ, reveals a role for Inka1 in mouse neural tube closure | |
| CN113577281A (zh) | 调控整合素β亚基的试剂和方法 | |
| Yoo et al. | Overexpression of Drosophila Rad51 protein (DmRad51) disrupts cell cycle progression and leads to apoptosis | |
| WO2004052092A1 (es) | Mamíferos no humanos mutantes deficientes en receptores sigma y sus aplicaciones | |
| JP2000515386A (ja) | Ｋｕ欠損細胞と非ヒトトランスジェニック動物 | |
| JP4118579B2 (ja) | Ｅｃａｔ５ノックアウト細胞 | |
| JP3646161B2 (ja) | Ｋｅａｐ１遺伝子改変による異物代謝系第二相強化非ヒト動物の作出方法 | |
| Motaln et al. | In situ analysis of Raidd-beta-galactosidase fusion gene expression in transgenic mouse midgestation embryos | |
| JP2008508887A (ja) | 真核細胞及び非ヒト動物における標的遺伝子の発現を調節するための誘導性発現系 | |
| JP2003506056A (ja) | 腫瘍抑制遺伝子ａｎｘ７のノックアウトマウス | |
| JPWO2008062904A1 (ja) | トランスジーンの安定的発現を可能にする方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120228 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20120228 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20120322 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120424 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120724 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121005 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130305 |